Ohr Pharmaceutical Announces Squalamine Eye Drop Presentation by Dr.Michael Elman at Macula Society 2012
NEW YORK, NY, Jun 15, 2012 (Menafn - MARKETWIRE via COMTEX) --Ohr Pharmaceutical Inc. OHRP announced today that MichaelJ. Elman, M.D., a member of Ohr Pharmaceutical's scientific advisoryboard, will be giving a presentation on the Squalamine Eye Dropprogram on Friday, June 15 at the Macula Society annual meetingtaking place in Jerusalem, Israel from June 11-15, 2012. Dr. Elman'spresentation will include an overview of Ohr's wet-AMD eye drop, itsclinical relevance, and future development areas.
About Ohr Pharmaceutical Inc. Ohr Pharmaceutical Inc. OHRP(www.ohrpharmaceutical.com) is a pharmaceutical company dedicated tothe clinical development of new drugs for underserved therapeuticneeds in large and growing markets. The company is focused on twolead compounds: Squalamine eye drops for the treatment of the wetform of age-related macular degeneration, and OHR/AVR118 for thetreatment of cancer cachexia, currently being investigated in a PhaseII trial.
About Squalamine Eye Drops Squalamine is an anti-angiogenic smallmolecule with a novel intracellular mechanism of action, thatcounteracts not only Vascular Endothelial Growth Factor ("VEGF") butalso other angiogenic growth factors such as Platelet Derived GrowthFactor ("PDGF") with high potency at nanomolar concentrations. Recentclinical evidence has shown PDGF to be an additional key target forthe treatment of wet-AMD. The drug was previously studied using anintravenous administration in over 250 patients in Phase 1 and Phase2 trials for the treatment of wet-AMD, with squalamine demonstratingfavorable biologic effect and maintained and improved visual acuityoutcomes, with both early and advanced lesions responding. OhrPharmaceutical has developed a novel eye drop of squalamine for thetreatment of wet-AMD designed for self-administration which mayprovide several potential advantages over the FDA approved currentstandards of care, Roche/Genentech's Lucentis(R) and Regeneron'sEylea(R), which require intravitreal injections directly into theeye. Preclinical testing has demonstrated that the eye dropformulation is both safe to ocular tissues and achieves in excess oftarget anti-angiogenic concentrations in the tissues of the back ofthe eye. In May 2012, the Squalamine eye drop program was grantedFast Track Designation by the U.S. FDA.
Safe Harbor Statement under the Private Securities Litigation ReformAct of 1995: This news release contains forward-looking statementswithin the meaning of the "safe harbor" provisions of the PrivateSecurities Litigation Reform Act of 1995. These forward-lookingstatements are made only as the date thereof, and Ohr Pharmaceuticalundertakes no obligation to update or revise the forward-lookingstatement whether as a result of new information, future events orotherwise. Our actual results may differ materially and adverselyfrom those expressed in any forward-looking statements as a result ofvarious factors and uncertainties, including the future success ofour scientific studies, our ability to successfully develop products,rapid technological change in our markets, changes in demand for ourfuture products, legislative, regulatory and competitivedevelopments, the financial resources available to us, and generaleconomic conditions. For example, there can be no assurance that Ohrwill be able to sustain operations for expected periods. Shareholdersand prospective investors are cautioned that no assurance of theefficacy of pharmaceutical products can be claimed or assured untilfinal testing; and no assurance or warranty can be made that the FDAor Health Canada will approve final testing or marketing of anypharmaceutical product. Ohr's most recent Annual Report andsubsequent Quarterly Reports discuss some of the important riskfactors that may affect our business, results of operations andfinancial condition. We disclaim any intent to revise or updatepublicly any forward-looking statements for any reason.
Tel: (877) 215-4813
SOURCE: Ohr Pharmaceutical Inc.
Copyright 2012 Marketwire, Inc., All rights reserved.